The effect of the top 20 Alzheimer disease risk genes on gray‐matter density and FDG PET brain metabolism
Abstract
We analyzed the effects of the top 20 Alzheimer disease (AD) risk genes on gray‐matter density (GMD) and metabolism.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jan 01, 2016
- Source ID
- 10.1016/j.dadm.2016.12.003
Entities
People
- Andrew J. Saykin
- David Elashoff
- Eddie Stage
- Holly Wilhalme
- John D. West
- Kwangsik Nho
- Liana G. Apostolova
- Meredith Phillips
- Naira Goukasian
- Shannon L. Risacher
- The Alzheimer’s Disease Neuroimaging Initiative*
- Triet M. Do
- Tugce Duran
Organizations
- AbbVie
- BioClinica
- Biogen
- Canadian Institutes of Health Research
- Chiron Corporation
- Eli Lilly and Company
- GE HealthCare
- Indiana University
- Laboratoires Servier
- Lundbeck
- National Institute of Biomedical Imaging and Bioengineering
- National Institute on Aging
- National Institutes of Health
- Norman Cousins Center for Psychoneuroimmunology
- Pfizer
- Roche (United States)
- Takeda Pharmaceutical Company
- UCLA David Geffen School of Medicine
- United States Department of Defense
- United States National Library of Medicine
- University of California, Los Angeles